Literature DB >> 6177374

Purified interferon as protection against rhinovirus infection.

G M Scott, R J Phillpotts, J Wallace, D S Secher, K Cantell, D A Tyrrell.   

Abstract

In a double-blind placebo-controlled study a preparation of human leucocyte interferon purified by affinity chromatography using a monoclonal antibody and applied by repeated nasal sprays reduced the incidence and severity of colds in volunteers challenged with human rhinovirus 9. Although interferon itself caused some symptoms, these were minor compared with the clinical colds. Interferon activity was still detectable in nasal washings as long as 26 hours after the last dose in about half the volunteers on active treatment.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6177374      PMCID: PMC1498753          DOI: 10.1136/bmj.284.6332.1822

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  11 in total

1.  Antiviral activity of intranasally applied human leukocyte interferon.

Authors:  S B Greenberg; M W Harmon; P E Johnson; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

2.  Distribution and removal of human serum albumin-technetium 99m instilled intranasally.

Authors:  F Y Aoki; J C Crowley
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

3.  Large-scale production of human leukocyte interferon containing 10(8) units per ml.

Authors:  K Cantell; S Hirvonen
Journal:  J Gen Virol       Date:  1978-06       Impact factor: 3.891

4.  Inhibition of respiratory virus infection by locally applied interferon.

Authors:  T C Merigan; S E Reed; T S Hall; D A Tyrrell
Journal:  Lancet       Date:  1973-03-17       Impact factor: 79.321

5.  Failure of human fibroblast interferon to protect against rhinovirus infection.

Authors:  G M Scott; S Reed; T Cartwright; D Tyrrell
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

6.  A monoclonal antibody for large-scale purification of human leukocyte interferon.

Authors:  D S Secher; D C Burke
Journal:  Nature       Date:  1980-06-12       Impact factor: 49.962

7.  Immunoradiometric assay of human leukocyte interferon using monoclonal antibody.

Authors:  D S Secher
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

8.  Work of a district ethical committee.

Authors:  M J Denham; A Foster; D A Tyrrell
Journal:  Br Med J       Date:  1979-10-27

9.  Human nasal epithelial cell culture system: evaluation of response to human interferons.

Authors:  M W Harmon; S B Greenberg; P E Johnson; R B Couch
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

10.  Recovery of applied human leukocyte interferon from the nasal mucosa of chimpanzees and humans.

Authors:  P E Johnson; S B Greenberg; M W Harmon; B R Alford; R B Couch
Journal:  J Clin Microbiol       Date:  1976-07       Impact factor: 5.948

View more
  23 in total

Review 1.  Cold comfort for the catarrhal child.

Authors:  D Isaacs
Journal:  Arch Dis Child       Date:  1990-12       Impact factor: 3.791

2.  The experimental and clinical use of immune-modulating drugs in the prophylaxis and treatment of infections.

Authors:  J Drews
Journal:  Infection       Date:  1985       Impact factor: 3.553

3.  Studies on 44 081 R.P., a new antirhinovirus compound, in cell cultures and in volunteers.

Authors:  A Zerial; G H Werner; R J Phillpotts; J S Willmann; P G Higgins; D A Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

4.  Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds.

Authors:  B M Farr; J M Gwaltney; K F Adams; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

5.  The experimental and clinical use of immune-modulating drugs in the prophylaxis and treatment of infections.

Authors:  J Drews
Journal:  Infection       Date:  1984 Mar-Apr       Impact factor: 3.553

6.  Antibody to human leucocyte interferon may enhance the frequency of rhinovirus isolation.

Authors:  R J Phillpotts
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

7.  Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers.

Authors:  P G Higgins; R J Phillpotts; G M Scott; J Wallace; L L Bernhardt; D A Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

Review 8.  Decoding the complexity of type I interferon to treat persistent viral infections.

Authors:  Elizabeth B Wilson; David G Brooks
Journal:  Trends Microbiol       Date:  2013-11-08       Impact factor: 17.079

9.  Prophylactic intranasal alpha 2 interferon and viral exacerbations of chronic respiratory disease.

Authors:  M J Wiselka; K G Nicholson; J Kent; J B Cookson; D A Tyrrell
Journal:  Thorax       Date:  1991-10       Impact factor: 9.139

Review 10.  The interferons.

Authors:  J L Toy
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.